280 related articles for article (PubMed ID: 25735680)
1. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families.
Gillies RL; Bjorksten AR; Du Sart D; Hockey BM
Anaesth Intensive Care; 2015 Mar; 43(2):157-66. PubMed ID: 25735680
[TBL] [Abstract][Full Text] [Related]
2. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
Beam TA; Loudermilk EF; Kisor DF
Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884
[TBL] [Abstract][Full Text] [Related]
4. DNA testing for malignant hyperthermia: the reality and the dream.
Stowell KM
Anesth Analg; 2014 Feb; 118(2):397-406. PubMed ID: 24445638
[TBL] [Abstract][Full Text] [Related]
5. Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.
Schiemann AH; Stowell KM
Br J Anaesth; 2016 Jul; 117(1):124-8. PubMed ID: 27147545
[TBL] [Abstract][Full Text] [Related]
7. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.
Tammaro A; Di Martino A; Bracco A; Cozzolino S; Savoia G; Andria B; Cannavo A; Spagnuolo M; Piluso G; Aurino S; Nigro V
Clin Genet; 2011 May; 79(5):438-47. PubMed ID: 20681998
[TBL] [Abstract][Full Text] [Related]
8. Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency.
Levano S; Gonzalez A; Singer M; Demougin P; Rüffert H; Urwyler A; Girard T
Neuromuscul Disord; 2017 May; 27(5):492-499. PubMed ID: 28259615
[TBL] [Abstract][Full Text] [Related]
9. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
Kraeva N; Sapa A; Dowling JJ; Riazi S
Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
[TBL] [Abstract][Full Text] [Related]
10. Genetic epidemiology of malignant hyperthermia in the UK.
Miller DM; Daly C; Aboelsaod EM; Gardner L; Hobson SJ; Riasat K; Shepherd S; Robinson RL; Bilmen JG; Gupta PK; Shaw MA; Hopkins PM
Br J Anaesth; 2018 Oct; 121(4):944-952. PubMed ID: 30236257
[TBL] [Abstract][Full Text] [Related]
11. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.
Fiszer D; Shaw MA; Fisher NA; Carr IM; Gupta PK; Watkins EJ; Roiz de Sa D; Kim JH; Hopkins PM
Anesthesiology; 2015 May; 122(5):1033-46. PubMed ID: 25658027
[TBL] [Abstract][Full Text] [Related]
12. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.
Kim JH; Jarvik GP; Browning BL; Rajagopalan R; Gordon AS; Rieder MJ; Robertson PD; Nickerson DA; Fisher NA; Hopkins PM
Anesthesiology; 2013 Nov; 119(5):1054-65. PubMed ID: 24013571
[TBL] [Abstract][Full Text] [Related]
13. Using exome data to identify malignant hyperthermia susceptibility mutations.
Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
[TBL] [Abstract][Full Text] [Related]
14. Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of
Sadhasivam S; Brandom BW; Henker RA; McAuliffe JJ
Pharmacogenomics; 2019 Sep; 20(14):989-1003. PubMed ID: 31559918
[No Abstract] [Full Text] [Related]
15. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.
Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I
Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084
[TBL] [Abstract][Full Text] [Related]
16. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort.
Broman M; Kleinschnitz I; Bach JE; Rost S; Islander G; Müller CR
Clin Genet; 2015 Oct; 88(4):381-5. PubMed ID: 25256590
[TBL] [Abstract][Full Text] [Related]
17. Genetics of malignant hyperthermia.
Brandom BW
ScientificWorldJournal; 2006 Dec; 6():1722-30. PubMed ID: 17195870
[TBL] [Abstract][Full Text] [Related]
18. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
19. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots.
Gillies RL; Bjorksten AR; Davis M; Du Sart D
Anaesth Intensive Care; 2008 May; 36(3):391-403. PubMed ID: 18564801
[TBL] [Abstract][Full Text] [Related]
20. Relevance of pathogenicity prediction tools in human RYR1 variants of unknown significance.
Hoppe K; Jurkat-Rott K; Kranepuhl S; Wearing S; Heiderich S; Merlak S; Klingler W
Sci Rep; 2021 Feb; 11(1):3445. PubMed ID: 33564012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
